Incretin Atlas › Trials › EloraTZP phase 2b (obesity + T2D)
EloraTZP phase 2b (obesity + T2D)
EloraTZP, Eloralintide, Tirzepatide · t2d
Design
- Molecule(s)
- EloraTZP, Eloralintide, Tirzepatide
- Population
- t2d
- Phase
- 2
- Duration
- 48 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EloraTZP 3/5 mg | t2d | 48 | — | −13.2 % vs −3.0 % Δ −10.2 pp | — | −2.2 vs −0.3 | — | — | — | — | — | — | press release |
| EloraTZP 6/5 mg | t2d | 48 | — | −19.4 % vs −3.0 % Δ −16.4 pp | — | −2.7 vs −0.3 | — | — | — | — | — | — | press release |
| EloraTZP 6/10 mg | t2d | 48 | — | −19.9 % vs −3.0 % Δ −16.9 pp | — | −2.6 vs −0.3 | — | — | — | — | — | — | press release |
| EloraTZP 9/15 mg | t2d | 48 | — | −23.3 % vs −3.0 % Δ −20.3 pp | — | −2.9 vs −0.3 | — | — | — | — | — | — | press release |
| eloralintide 3 mg | t2d | 48 | — | −8.2 % vs −3.0 % Δ −5.2 pp | — | −1.1 vs −0.3 | — | — | — | — | — | — | press release |
| eloralintide 6 mg | t2d | 48 | — | −12.3 % vs −3.0 % Δ −9.3 pp | — | −1.4 vs −0.3 | — | — | — | — | — | — | press release |
| eloralintide 9 mg | t2d | 48 | — | −11.1 % vs −3.0 % Δ −8.1 pp | — | −1.3 vs −0.3 | — | — | — | — | — | — | press release |
| tirzepatide 15 mg | t2d | 48 | — | −14.8 % vs −3.0 % Δ −11.8 pp | — | −2.4 vs −0.3 | 2.9 vs 16.7 | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- EloraTZP 3/5 mg: eloralintide 3 mg + tirzepatide 5 mg (separate injections)
- EloraTZP 6/5 mg: eloralintide 6 mg + tirzepatide 5 mg (separate injections)
- EloraTZP 6/10 mg: eloralintide 6 mg + tirzepatide 10 mg (separate injections)
- EloraTZP 9/15 mg: eloralintide 9 mg + tirzepatide 15 mg (separate injections)
Verbatim quotes from the source (9)
- EloraTZP 3/5 mg · weight_eff · press release table
Elora 3 mg + TZP 5 mg -13.2
- EloraTZP 6/5 mg · weight_eff · press release table
Elora 6 mg + TZP 5 mg -19.4
- EloraTZP 6/10 mg · weight_eff · press release table
Elora 6 mg + TZP 10 mg -19.9
- EloraTZP 9/15 mg · weight_eff · press release table
Elora 9 mg + TZP 15 mg -23.3
- eloralintide 3 mg · weight_eff · press release table
Elora 3 mg -8.2 %
- eloralintide 6 mg · weight_eff · press release table
Elora 6 mg -12.3 %
- eloralintide 9 mg · weight_eff · press release table
Elora 9 mg -11.1 %
- tirzepatide 15 mg · weight_eff · press release
tirzepatide 15 mg reduced body weight by an average of 34.4 lbs (14.8%
- tirzepatide 15 mg · ae_dc · press release, safety paragraph
Treatment discontinuation rates due to adverse events were 10.8% to 27.0% with EloraTZP, 0% to 10.8% with eloralintide, 2.9% with tirzepatide and 16.7% with placebo.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: EloraTZP phase 2b (obesity + T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/eloratzp-phase-2b/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.